Ma­jor FDA staff cuts would slow drug re­views, ex­perts say

The Trump ad­min­is­tra­tion’s re­port­ed plans to po­ten­tial­ly lay off thou­sands of FDA em­ploy­ees could slow the agency’s re­views of new drugs, ex­perts say, in ad­di­tion …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER